Journal article icon

Journal article

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

Abstract:
Background The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event. Methods ARRIVE is a randomised, double-blind, placebo-controlled, multicentre study done in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascul... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1016/s0140-6736(18)31924-x

Authors


Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
Lancet Journal website
Volume:
392
Issue:
10152
Pages:
1036-1046
Publication date:
2018-08-26
Acceptance date:
2018-08-10
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Pubs id:
pubs:915413
URN:
uri:4e5a6dcf-538c-41e1-88b9-1cca43fdb87a
UUID:
uuid:4e5a6dcf-538c-41e1-88b9-1cca43fdb87a
Local pid:
pubs:915413

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP